H.C. Wainwright Initiates Coverage of Evotec (EVO) with a Buy Rating

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy and Hold Under $5.

On April 14, 2026, H.C. Wainwright assumed coverage of Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target, citing the company’s shift from a legacy asset-heavy integrated model toward a more streamlined and capital-efficient structure. The firm views current share levels as an attractive entry point for long-term investors.

On the same day, Evotec SE (NASDAQ:EVO) announced the appointment of Ingrid Müller as Chief Operating Officer, effective May 1. She will join the company’s management board and oversee global operations as well as the execution of Evotec’s Horizon initiative. Müller most recently served as VP of portfolio strategy and execution at CureVac.

BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42

Pixabay/Public Domain

Last month, Deutsche Bank analyst Fynn Scherzler lowered the price target on Evotec SE (NASDAQ:EVO) to €4.50 from €6 previously and maintained a Hold rating on Evotec SE (NASDAQ:EVO) shares.

Evotec SE (NASDAQ:EVO) provides drug discovery and development services across multiple therapeutic areas globally.

While we acknowledge the risk and potential of EVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVO and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.